ICI Therapy

Phase 1Small molecule

IIndiana University

ICI Therapy is one of 6 small molecule programs targeting Gastrointestinal Neoplasms. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastrointestinal NeoplasmsNot yet recruiting

Gastrointestinal NeoplasmsPhase 1

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Gastrointestinal Neoplasms

#DrugCompanyPhaseTrials

Velzatinib

GSK

Phase 2

2 2

GSK5764227

GSK

Preclinical

1 3

IDRX-42

GSK

Phase 1

2 4

Drug

EElro Pharma

Preclinical

1 5

ICI Therapy

IIndiana University

Phase 1

1 6

Risvutatug Rezetecan

NNader Sanai

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Gastrointestinal Neoplasms

NCT07389525

Clinical

Trials by Indication[1]

Gastrointestinal Neoplasms1 trial

Assessment of Drug-Drug Interactions Between Immune Checkpoint Inhibitors and Cytochrome P450 Substrates: Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

Not yet recruiting·IIndiana University·Phase 1·NCT07389525·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ICI Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ICI Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ICI Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IIndiana University

ICI Therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Gastrointestinal Neoplasms1 trial

References

Drug Info

Quick Facts

Related News